HIGHLIGHTS & NEWS

MeiraGTx, a clinical-stage genetic medicine company with a global footprint, is focused on developing potentially curative treatments for patients living with serious diseases.

MeiraGTx is pioneering transformative technologies that allow precise control of gene expression using proprietary oral small molecules. Our gene regulation platform includes synthetic riboswitches, rationally designed for mammalian cells. This gene regulation system provides an unprecedented platform for spatial and temporal control of gene therapy, with broad implications for the applicability of genetic medicines for treating a wide range of potential disorders not limited to inherited diseases.

We have multiple ongoing clinical programs, one compassionate use program and a broad pipeline of preclinical and research programs.

Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.

Each day we work to improve the lives of patients through cutting-edge science designed to treat their specific disease. We believe each patient deserves the best treatment possible, and with our highly flexible genetic medicine platform and manufacturing process, we believe we can deliver on that promise.

More About Us